INCY News and Press, Incyte Corporation From 05/08/23

Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective Jun...

2023-05-02 12:08:04 ET Incyte Corporation (INCY) Q1 2023 Earnings Conference Call May 02, 2023, 8:00 AM ET Company Participants Christine Chiou - Head of Investor Relations Herve Hoppenot - President and Chief Executive Officer Barry Flannelly - Executive Vice Pr...

2023-05-02 07:46:25 ET Incyte ( NASDAQ: INCY ) stock was trading in the red premarket on Tuesday after Q1 results missed estimates, but the company tightened its 2023 net product revenues outlook for bone marrow cancer drug Jakafi. Adjusted EPS declined -32.7% to $0.37...

2023-05-02 07:02:02 ET Incyte press release ( NASDAQ: INCY ): Q1 Non-GAAP EPS of $0.37 misses by $0.37 . Revenue of $808.67M (+10.3% Y/Y) misses by $49.92M . "Our first quarter results demonstrate continued year-over-year double-digit revenue growth driven by J...

– Total net product revenues of $693 million in Q1'23 (+14% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023 – Opzel...

– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of O...

2023-04-20 11:32:46 ET The European Commission (EC) approved Incyte's ( NASDAQ: INCY ) Opzelura cream to treat non-segmental vitiligo with facial involvement in patients 12 years of age and older. The company said that Opzelura (ruxolitinib) is the first and only top...

Opzelura ® (ruxolitinib) Cream is the first approved treatment in the European Union (EU) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improved facial and total body repigmentation, sustained...

2023-04-18 10:45:54 ET Summary Incyte Corp. has strong growth in their two main drugs, Jakafi and Opzelura. Jakafi patent expires in 5 years, with no current solution. Opzelura is growing, but still uncertain in potential market size. Incyte is currently overweight and is ...

2023-04-17 09:02:31 ET Summary With billions in revenues and modest growth, Incyte has an elephantine problem. Incyte is building a three pronged stool of therapies to generate revenues outside Jakafi. Its financial position is fully supportive of its efforts to bolster Jakafi...